TNXP_OUT_1 [2025-03-21 11:20:40 -0400] 2279 Bytes | 601 tokens | Cum: 601 tkns (7.51% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Tonix Pharmaceuticals (TNXP) hit my radar screen, up to 21.66 from a prev close of 18.19 Do you think its got more juice or is it lacking potential? It's 11:20:38 AM on Fri Mar 21, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for Tonix Pharmaceuticals:

C1 - Mar-20-25 07:00AM - As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
C2 - Mar-18-25 04:30PM - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
C3 - Mar-14-25 08:35AM - Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
C4 - Mar-13-25 07:00AM - Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
C5 - Mar-12-25 01:12PM - Life Sciences Investor Forum Agenda Announced for March 13th
C6 - Mar-12-25 01:12PM 07:30AM - Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
C7 - Mar-11-25 07:00AM - Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
C8 - Mar-10-25 08:00AM - Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Tonix Pharmaceuticals (TNXP)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TNXP_OUT_3 [2025-03-21 11:20:49 -0400] 1039 Bytes | 296 tokens | Cum: 899 tkns (11.24% of 8k)
==========================================================================

Showing C2 (chunk 1 of 19): C2:
**Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights**
Date: Mar-18-25 04:30PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/18/3045000/28908/en/Tonix-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Operational-Highlights.html

March 18, 2025 16:30 ET| Source:Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals Holding Corp.

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years

Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024

Announced positive t

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_5 [2025-03-21 11:20:51 -0400] 1041 Bytes | 250 tokens | Cum: 1151 tkns (14.39% of 8k)
==========================================================================

Showing C2 (chunk 2 of 19): opline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases

Received government grant for potential mpox vaccine, TNX-801, which has demonstrated single-dose immune protection against a monkeypox challenge in non-human primates

Received first payments from U.S. Department of Defense (DoD) contract for up to $34 million over five years to develop a broad-spectrum antiviral drug program

CHATHAM, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent operational highlights.

“Wi

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_7 [2025-03-21 11:20:53 -0400] 1025 Bytes | 291 tokens | Cum: 1444 tkns (18.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T14:20:05Z - InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine...
A2 - 2025-03-20T11:07:12Z - As Mpox Cases Spread Around The World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potent...
A3 - 2025-03-20T11:10:52Z - Tonix Pharmaceuticals Holding: As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-...
A4 - 2025-03-19T17:30:08Z - Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail's Feeling Bullish...
A5 - 2025-03-19T17:06:06Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Biodexa Pharmaceuticals (NASDAQ:BDRX)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TNXP_OUT_9 [2025-03-21 11:20:55 -0400] 1038 Bytes | 290 tokens | Cum: 1736 tkns (21.70% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine for Mpox**Date: 2025-03-20Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Investor+Brand+Network/InvestorNewsBreaks+%E2%80%93+Tonix+Pharmaceuticals+Holding+Corp.+%28NASDAQ%3A+TNXP%29+Advances+Single-Dose+Vaccine+for+Mpox/24527310.htmlTonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicating recombinant virus vaccine designed to protect against mpox. The company reports that TNX-801 has demonstrated single-dose immunity and superior tolerability compared to 20th-century vaccinia vaccines in animal studies. As a new strain of mpox, Clade I, spreads globally -- including recent cases in the U.S. -- health officials are seek

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_11 [2025-03-21 11:20:57 -0400] 986 Bytes | 298 tokens | Cum: 2036 tkns (25.45% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-11T11:00:00Z - Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
B2 - 2025-03-03T18:00:00Z - Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight
B3 - 2025-02-05T12:00:00Z - Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
B4 - 2024-11-26T12:00:00Z - Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
B5 - 2024-11-01T11:00:00Z - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
B6 - 2024-10-29T12:00:00Z - Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNXP_OUT_13 [2025-03-21 11:21:00 -0400] 719 Bytes | 186 tokens | Cum: 2224 tkns (27.80% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/11/3040395/28908/en/Tonix-Pharmaceuticals-to-Present-at-the-Zacks-SCR-Life-Sciences-Virtual-Investor-Forum-on-March-13th.htmlTonix Pharmaceuticals, a biopharmaceutical company, announced that its CEO will present at the Zacks SCR Life Sciences Virtual Investor Forum. The company's pipeline includes drug candidates for pain management, vaccines, and other therapeutic areas.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_15 [2025-03-21 11:21:01 -0400] 1071 Bytes | 295 tokens | Cum: 2555 tkns (31.94% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 10-K ITEM 7 MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

This Mgts Discussion and Analysis of Fin Cond and Results of Oper includes a number of forward-looking statements that reflect Mgts current views with res...

S2 - 2025-03-10 8-K Item 7.01. Regulation FD Disclosure.

On March 10, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced it was awarded a grant for $50,000 from the Medical CBRN Defense Consortium (MCDC) to support the development of its TNX-801 (recombinant horsepox virus, live vac...

S3 - 2025-03-04 8-K Item 9.01 Fin Stmnts and Exhibits.

(d) Exhibit

No.

Description. 10.01

Employment Agrmt, by and between Tonix Pharma Limited and Siobhan Fogarty, dated February 27, 2025 *

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Certa...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNXP_OUT_17 [2025-03-21 11:21:03 -0400] 1038 Bytes | 207 tokens | Cum: 2764 tkns (34.55% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Managements Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Managements current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as may will, expect, anticipate, believe, estimate and continue, or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of its management team as well as the assumptions on which such statements are based and should be read together with the Risk Factors section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by t

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_19 [2025-03-21 11:21:05 -0400] 1038 Bytes | 211 tokens | Cum: 2977 tkns (37.21% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): he forward-looking statements contained in the following discussion and analysis. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report and in other reports we file with the Securities and Exchange Commission, particularly those under Risk Factors..

We are a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Our development portfolio is focused on central nervous system (CNS) disorders. Our priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act)

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_21 [2025-03-21 11:21:07 -0400] 1038 Bytes | 243 tokens | Cum: 3222 tkns (40.27% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonixs CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the National Institute on Drug Abuse. Tonixs immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-liga

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_23 [2025-03-21 11:21:24 -0400] 4866 Bytes | 1388 tokens | Cum: 4612 tkns (57.65% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+
| Volume: 1,530,426 | SMA50: 14.96% | Market Cap: 138.86M | Option/Short: No / Yes | Sales past 5Y: 5.99% | Sales Surprise: -19.31% |
+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+
| Avg Volume: 1.50M | SMA200: -48.56% | Shs Outstand: 4.39M | Short Float: - | Employees: 81 | EPS Surprise: 47.19% |
+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+
| Rel Volume: 3.62 | Perf Week: 43.87% | Shs Float: - | Short Ratio: 0.37 | Debt/Eq: 0.06 | P/E: - |
+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+
| RSI (14): 62.01 | Perf Month: 123.16% | Inst Own: 2.86% | Short Interest: 0.55M | Sales Y/Y TTM: 29.94% | Earnings: Mar 18 AMC |
+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+
| ATR (14): 3.24 | Perf Quarter: -35.37% | Insider Own: 0.00% | Beta: 1.59 | ROE: -106.12% | |
+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+
| SMA20: 67.75% | Index: - | Insider Trans: - | Sales Q/Q: -31.68% | ROI: -89.94% | |
+-------------------+-----------------------+---------------------+------------------------+-----------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Tonix Pharmaceuticals Holding Corp. (TNXP) by Bell Margaret Smith (Unknown Title) on 2025-02-05
- Common Stock, par value $0.001: 1 shares at $0.15 (D) Footnote: Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock.

Inside Trans: Tonix Pharmaceuticals Holding Corp. (TNXP) by Treco James (Unknown Title) on 2025-02-05
- Common Stock, par value $0.001: 0.02 shares at $0.3 (D) Footnote: Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock.

[Company Financial Summary]
[Company Details]
Name: Tonix Pharmaceuticals Holding Corp.
Market Cap: 117253993.43
Shares Outstanding: 5590445
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 10094000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -130036000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 21.78
Average Volume: 1684134.3
30-Day High: 21.78
30-Day Low: 7.38

[Detailed Financials: TTM 2024]
- Total Assets: $162,890,000.0
- Total Liabilities: $23,332,000.0
- Total Equity: $139,558,000.0
- Current Assets: $119,002,000.0
- Current Liabilities: $18,307,000.0

[Income Statement: TTM 2024]
- Revenue: $10,094,000.00
- Net Income: $-130,036,000.0
- Operating Income: $-136,701,000.0
- Earnings Per Share (EPS): -176.6

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $73,831,000.0

[Detailed Financials: FY 2024]
- Total Assets: $162,890,000.0
- Total Liabilities: $23,332,000.0
- Total Equity: $139,558,000.0
- Current Assets: $119,002,000.0
- Current Liabilities: $18,307,000.0

[Income Statement: FY 2024]
- Revenue: $10,094,000.00
- Net Income: $-130,036,000.0
- Operating Income: $-136,701,000.0
- Earnings Per Share (EPS): -176.6

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $73,831,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TNXP_OUT_25 [2025-03-21 11:21:27 -0400] 676 Bytes | 167 tokens | Cum: 5038 tkns (62.98% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TNXP_IN_27 [2025-03-21 11:21:28 -0400] 126 Bytes | 29 tokens | Cum: 5095 tkns (63.69% of 8k)
==========================================================================

====================================
[2025-03-21 08:21:28] # Analysis Completed
Elapsed Time: 50.02 seconds